PD-1 and PD-L1 have been investigated given the described efficacy of checkpoint inhibitors; however, there was no difference in expression of PD-1/PD-L1 in MS tested, and they may instead have more impact in the surrounding tumor microenvironment [92,93]. The gene discussed is CD274; the disease is neoplasm.